174 related articles for article (PubMed ID: 18802723)
1. 'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring.
Kühnemund A; Liebisch P; Bauchmüller K; zur Hausen A; Veelken H; Wäsch R; Engelhardt M
J Cancer Res Clin Oncol; 2009 Mar; 135(3):477-84. PubMed ID: 18802723
[TBL] [Abstract][Full Text] [Related]
2. [Research Advance in Light Chain Escape of Multiple Myeloma -Review].
Huang QC; Ding JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1833-1836. PubMed ID: 29262926
[TBL] [Abstract][Full Text] [Related]
3. Monitoring myeloma: light chain isotype suppression. A new parameter.
Wearne A; Joshua DE; Kronenberg H
Aust N Z J Med; 1985 Oct; 15(5):629-33. PubMed ID: 3937514
[TBL] [Abstract][Full Text] [Related]
4. Interpretation Difficulties of Serum Immunofixation Test in Immunoglobulin D Multiple Myeloma with Hidden Lambda Light Chains.
Biaz A; Uwingabiye J; Rachid A; Dami A; Bouhsain S; Ouzzif Z; Idrissi SEM
Clin Lab; 2018 Jun; 64(6):1065-1069. PubMed ID: 29945318
[TBL] [Abstract][Full Text] [Related]
5. An infrequent relapse of multiple myeloma predominantly manifesting as light chain escape: clinical experience from two Chinese centers.
Qu X; Zhang L; Fu W; Zhang H; Xiang X; Qiu L; Hou J
Leuk Lymphoma; 2010 Oct; 51(10):1844-9. PubMed ID: 20846099
[TBL] [Abstract][Full Text] [Related]
6. New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
Caldini A; Nozzoli C; Terreni A; Staderini M; Berardi M; Biagioli T; Brogi M; Bosi A
Clin Chem Lab Med; 2016 Jun; 54(6):991-5. PubMed ID: 26581069
[TBL] [Abstract][Full Text] [Related]
7. Antigenic properties of human IgG Kappa and IgG lambda myeloma plasma cells.
Hagner G
Exp Hematol; 1983 Mar; 11(3):219-25. PubMed ID: 6403367
[TBL] [Abstract][Full Text] [Related]
8. Reporting Apparent Biclonal Immunoglobulin-A Monoclonal Proteins with Identical Light Chains.
Jialal I; Kim KY; Rajappa P
Ann Clin Lab Sci; 2020 Jul; 50(4):541-544. PubMed ID: 32826253
[TBL] [Abstract][Full Text] [Related]
9. Correlations among different markers determined by immunochemical methods used for the diagnosis and monitoring of intact immunoglobulin multiple myeloma cases.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2012; 71(4):183-200. PubMed ID: 23755700
[TBL] [Abstract][Full Text] [Related]
10. Nonsecretory and Light Chain Escape in Patients With Multiple Myeloma.
Patel UH; Drabick JJ; Malysz J; Talamo G
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e515-e519. PubMed ID: 30201257
[TBL] [Abstract][Full Text] [Related]
11. [Atypical picture of lambda and kappa light chain multiple myeloma with lymphoplasmocytic infiltration of the bone marrow].
Gotić M; Rolović Z; Milosević N; Brkić S; Vuković S; Jovanović V; Ruvidić R
Srp Arh Celok Lek; 1988; 116(11-12):1041-9. PubMed ID: 3150132
[No Abstract] [Full Text] [Related]
12. [Clinical Significance of sFLC/MP Level and Light Chain Escape in Patients with Multiple Myeloma Relapse].
Xiang X; Chai Y; Wang X; Ma CC; Wang Y; Li YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1837-1844. PubMed ID: 34893120
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
14. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
[TBL] [Abstract][Full Text] [Related]
15. Generalized acquired cutis laxa associated with multiple myeloma with biphenotypic IgG-λ and IgA-κ gammopathy following treatment of a nodal plasmacytoma.
New HD; Callen JP
Arch Dermatol; 2011 Mar; 147(3):323-8. PubMed ID: 21422340
[TBL] [Abstract][Full Text] [Related]
16. Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Bianchi G; Richardson PG; Anderson KC
J Clin Oncol; 2014 Jul; 32(20):2125-32. PubMed ID: 24888801
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of monoclonal protein in 72 cases of multiple myeloma].
Yang JJ; Zhang GS; Chen XR
Hunan Yi Ke Da Xue Xue Bao; 2001 Apr; 26(2):152-4. PubMed ID: 12536652
[TBL] [Abstract][Full Text] [Related]
18. Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains.
Jiwani S; Bornhost J; Alapat D
Int J Clin Exp Pathol; 2015; 8(7):8536-44. PubMed ID: 26339430
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
